Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Orphanet Journal of Rare Diseases
Published in: Orphanet Journal of Rare Diseases 1/2011

Open Access 01-12-2011 | Research

Cognitive development in patients with Mucopolysaccharidosis type III (Sanfilippo syndrome)

Authors: Marlies J Valstar, Jan Pieter Marchal, Martha Grootenhuis, Vivian Colland, Frits A Wijburg

Published in: Orphanet Journal of Rare Diseases | Issue 1/2011

Login to get access

Abstract

Background

Mucopolysaccharidosis type III (MPS III, Sanfilippo syndrome) is a lysosomal storage disorder caused by a deficiency of one of the enzymes involved in the degradation of heparan sulfate.
MPS III is characterized by progressive mental deterioration resulting in severe dementia. A number of potentially disease-modifying therapies are studied. As preservation of cognitive function is the ultimate goal of treatment, assessment of cognitive development will be essential in order to evaluate treatment efficacy. However, no large scale studies on cognitive levels in MPS III patients, using formal psychometric tests, have been reported.

Methods

We aimed to assess cognitive development in all 73 living patients with MPS III in the Netherlands.

Results

Cognitive development could be assessed in 69 patients. In 39 of them developmental level was estimated > 3 months and formal psychometric testing was attempted. A remarkable variation in the intellectual disability was detected.

Conclusions

Despite special challenges encountered, testing failed in only three patients. The observed broad variation in intellectual disability, should be taken into account when designing therapeutic trials.
Appendix
Available only for authorised users
Literature
1.
2.
Ruijter GJ, Valstar MJ, van de Kamp JM, van der Helm RM, Durand S, van Diggelen OP, et al: Clinical and genetic spectrum of Sanfilippo type C (MPS IIIC) disease in The Netherlands. Mol Genet Metab. 2007.
3.
Valstar MJ, Neijs S, Bruggenwirth HT, Olmer R, Ruijter GJ, Wevers RA, et al: Mucopolysaccharidosis type IIIA: clinical spectrum and genotype-phenotype correlations. Ann Neurol. 2010, 68: 876-887. 10.1002/ana.22092.CrossRefPubMed
4.
Valstar MJ, Bruggenwirth HT, Olmer R, Wevers RA, Verheijen FW, Poorthuis BJ, et al: Mucopolysaccharidosis type IIIB may predominantly present with an attenuated clinical phenotype. J Inherit Metab Dis. 2010, 33: 759-767. 10.1007/s10545-010-9199-y.PubMedCentralCrossRefPubMed
5.
Malm G, Mansson JE: Mucopolysaccharidosis type III (Sanfilippo disease) in Sweden: clinical presentation of 22 children diagnosed during a 30-year period. Acta Paediatr. 2010.
6.
Meyer A, Kossow K, Gal A, Muhlhausen C, Ullrich K, Braulke T, et al: Scoring evaluation of the natural course of mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A). Pediatrics. 2007, 120: e1255-e1261. 10.1542/peds.2007-0282.CrossRefPubMed
7.
Meyer A, Kossow K, Gal A, Steglich C, Muhlhausen C, Ullrich K, et al: The mutation p.Ser298Pro in the sulphamidase gene (SGSH) is associated with a slowly progressive clinical phenotype in mucopolysaccharidosis type IIIA (Sanfilippo A syndrome). Hum Mutat. 2008, 29: 770.CrossRefPubMed
8.
Verhoeven WM, Csepan R, Marcelis CL, Lefeber DJ, Egger JI, Tuinier S: Sanfilippo B in an elderly female psychiatric patient: a rare but relevant diagnosis in presenile dementia. Acta Psychiatr Scand. 2009.
9.
Nidiffer FD, Kelly TE: Developmental and degenerative patterns associated with cognitive, behavioural and motor difficulties in the Sanfilippo syndrome: an epidemiological study. J Ment Defic Res. 1983, 27 (Pt 3): 185-203.PubMed
10.
Berger-Plantinga EG, Vanneste JA, Groener JE, van Schooneveld MJ: Adult-onset dementia and retinitis pigmentosa due to mucopolysaccharidosis III-C in two sisters. J Neurol. 2004, 251: 479-481. 10.1007/s00415-004-0368-5.CrossRefPubMed
11.
Moog U, van M, van Schrojenstein Lantman-de Valk HM, Spaapen L, Maaskant MA, Curfs LM: Is Sanfilippo type B in your mind when you see adults with mental retardation and behavioral problems?. Am J Med Genet C Semin Med Genet. 2007, 145C: 293-301. 10.1002/ajmg.c.30142.CrossRefPubMed
12.
Hemsley KM, King B, Hopwood JJ: Injection of recombinant human sulfamidase into the CSF via the cerebellomedullary cistern in MPS IIIA mice. Mol Genet Metab. 2007, 90: 313-328. 10.1016/j.ymgme.2006.10.005.CrossRefPubMed
13.
Malinowska M, Wilkinson FL, Langford-Smith KJ, Langford-Smith A, Brown JR, Crawford BE et al: Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease. PLoS One. 2010, 5: e14192. 10.1371/journal.pone.0014192.PubMedCentralCrossRefPubMed
14.
15.
Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van WS et al: The frequency of lysosomal storage diseases in The Netherlands. Hum Genet. 1999, 105: 151-156.CrossRefPubMed
16.
Van der Meulen BF, Ruiter SAJ, Lutje Spelberg HC, Smrkovsky M: Handleiding BSID-II NL. Lisse: Swets Test Publishers; 2002.
17.
Tellegen PJ, Winkel M, Wijberg-Williams BJ, Laros JA, Snijders-Oomen : niet-verbale intelligentietest SON-R 2,5-7. Lisse: Swets & Zeitlinger. 1996.
18.
Kort W, Schittekatte M, Dekker PH, Verhaeghe P, Compaan EL, Bosmans M, et al: WISC-III NL Handleiding en Verantwoording. London: The Psychological Corporation; 2005.
19.
de Bildt A, Kraijer D, Sytema S, Minderaa R: The psychometric properties of the Vineland Adaptive Behavior Scales in children and adolescents with mental retardation. J Autism Dev Disord. 2005, 35: 53-62. 10.1007/s10803-004-1033-7.CrossRefPubMed
20.
Piotrowska E, Jakobkiewicz-Banecka J, Baranska S, Tylki-Szymanska A, Czartoryska B, Wegrzyn A et al: Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses. Eur J Hum Genet. 2006, 14: 846-852. 10.1038/sj.ejhg.5201623.CrossRefPubMed
21.
Shapiro EG, Lockman LA, Balthazor M, Krivit W: Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. J Inherit Metab Dis. 1995, 18: 413-429. 10.1007/BF00710053.CrossRefPubMed
22.
Haxby JV: Neuropsychological evaluation of adults with Down's syndrome: patterns of selective impairment in non-demented old adults. J Ment Defic Res. 1989, 33 (Pt 3): 193-210.PubMed
23.
Valstar MJ, Ruijter GJ, van Diggelen OP, Poorthuis BJ, Wijburg FA: Sanfilippo syndrome: A mini-review. J Inherit Metab Dis. 2008.
24.
Manzi B, Loizzo AL, Giana G, Curatolo P: Autism and metabolic diseases. J Child Neurol. 2008, 23: 307-314. 10.1177/0883073807308698.CrossRefPubMed
25.
de Ruijter J, Valstar MJ, Wijburg FA: Mucopolysaccharidosis Type III (Sanfilippo Syndrome): Emerging Treatment Strategies. Curr Pharm Biotechnol. 2011, 12 (6): 923-30. 10.2174/138920111795542651.CrossRefPubMed
26.
Andermann A, Blancquaert I, Beauchamp S, Déry V: Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. 2008, Bull World Health Organ, 86 (4): 317-9.
Metadata
Title
Cognitive development in patients with Mucopolysaccharidosis type III (Sanfilippo syndrome)
Authors
Marlies J Valstar
Jan Pieter Marchal
Martha Grootenhuis
Vivian Colland
Frits A Wijburg
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2011
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/1750-1172-6-43

Other articles of this Issue 1/2011

Orphanet Journal of Rare Diseases 1/2011 Go to the issue

Research

Lack of a synergistic effect of a non-viral ALS gene therapy based on BDNF and a TTC fusion molecule

Research

At-Risk Phenotype of Neurofibromatose-1 Patients: A Multicentre Case-Control Study

Research

Utero-vaginal aplasia (Mayer-Rokitansky-Küster-Hauser syndrome) associated with deletions in known DiGeorge or DiGeorge-like loci

Research

Genome-wide association study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Europe

Research

Lidocaine for systemic sclerosis: a double-blind randomized clinical trial

Research

Oxytocin may be useful to increase trust in others and decrease disruptive behaviours in patients with Prader-Willi syndrome: a randomised placebo-controlled trial in 24 patients